Valuation: BioNTech SE

Market Cap 19.59B 21.66B 18.08B 16.36B 30.88B 2,036B 31.81B 217B 86.24B 1,089B 81.29B 79.55B 3,465B P/E 2026 *
-12.4x
P/E 2027 * -15.5x
Enterprise Value 8.43B 9.33B 7.78B 7.05B 13.3B 877B 13.7B 93.44B 37.13B 469B 35B 34.26B 1,492B EV / Sales 2026 *
4.55x
EV / Sales 2027 * 5.23x
Free-Float
94.76%
Yield 2026 *
-
Yield 2027 * -
1 day-2.91%
1 week-0.79%
Current month-3.39%
1 month-11.12%
3 months-8.15%
6 months-9.05%
Current year-10.52%
1 week 84.8
Extreme 84.8
88.78
1 month 84.8
Extreme 84.8
93.08
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
374.58
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 61 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 56 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
9/10/26 Sell

Chief Executive Officer

-36,209 0.0150%
7/10/26 Sell

Chief Executive Officer

-24,000 0.0099%
5/10/26 Sell

Chief Executive Officer

-72,000 0.0298%
Change 5-day change 1-year change 3-year change Capi.($)
-2.86%-0.79%-23.74%-13.01% 21.73B
+1.10%+1.03%+62.53%+70.47% 67.53B
+1.28%+8.71%+13.96%+92.70% 60.74B
+0.36%-0.95%+20.09%+98.45% 55.66B
-0.93%+7.67%+10.46%+109.68% 47.97B
-1.31%+2.46%+22.87%+40.14% 45.24B
-1.82%-0.24%+169.22%+801.91% 39.08B
+1.21%+4.75%+27.30%+52.81% 35.34B
-0.87%-2.89%+79.60%+56.33% 33.45B
-2.05%+8.57%-39.26%+394.06% 26.49B
Average -0.57%+2.09%+34.30%+170.35% 43B
Weighted average by Cap. -0.22%+2.57%+37.88%+157.40%

Financials

2026 *2027 *
Net sales 1.85B 2.05B 1.71B 1.55B 2.92B 193B 3.01B 20.54B 8.16B 103B 7.7B 7.53B 328B 1.86B 2.06B 1.72B 1.55B 2.93B 193B 3.02B 20.61B 8.19B 103B 7.72B 7.56B 329B
Net income -1.54B -1.7B -1.42B -1.28B -2.42B -160B -2.5B -17.03B -6.77B -85.43B -6.38B -6.24B -272B -1.23B -1.36B -1.14B -1.03B -1.94B -128B -2B -13.66B -5.43B -68.5B -5.12B -5.01B -218B
Net Debt -11.15B -12.33B -10.29B -9.32B -17.58B -1,159B -18.11B -124B -49.1B -620B -46.29B -45.3B -1,973B -9.87B -10.91B -9.11B -8.24B -15.55B -1,026B -16.02B -109B -43.44B -548B -40.94B -40.07B -1,745B
Projected Income Statement - Annual - BioNTech SE
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
13/11/26 US$85.04 -2.98% 971,741
11/11/26 US$87.65 +0.50% 766,155
10/11/26 US$87.21 -0.34% 693,533
09/11/26 US$87.51 0.00% 1,142,937
06/11/26 US$87.51 +1.92% 724,189
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - BioNTech SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
79.00EUR
Average target price
101.92EUR
Spread / Average Target
+29.02%
  1. Stock Market
  2. Stocks
  3. BNTX Stock